Monday 28 Apr, 2025 03:53 PM
Site map | Locate Us | Login
   IDBI Bank gains after Q4 PAT rises 26% YoY to Rs 2,051cr    Shree Digvijay Cement ends lower after weak Q4 performance    IRFC slips as Q4 PAT declines 2% YoY to Rs 1,682 cr    Zensar Tech gains after Q4 PAT climbs 10% QoQ to Rs 177 cr    Kopran jumps as USFDA inspection at subsidiary's plant concludes smoothly    Tejas Networks Ltd leads losers in 'A' group    SML Isuzu stuck in reverse gear as M&M's bid underwhelms    GACM Technologies Ltd leads losers in 'B' group    Volumes spurt at Ramkrishna Forgings Ltd counter    MRPL slides as Q4 PAT tumble 68% YoY to Rs 363 cr; GRM drops to $6.23/barrel    ICRA reaffirms ratings of Indraprastha Medical Corp; maintains 'stable' outlook    JSW Energy Ltd eases for fifth straight session    IDFC First Bank Q4 PAT slumps 58% YoY to Rs 304 cr; NII rises 10% YoY    Sigachi Industries inks MoU with Czech Republic-based Respilon Group    Lloyd Metals drops after Q4 PAT slips 27% YoY to Rs 202 cr 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Marksans Pharma gains as USFDA concludes inspection at New York unit
28-Apr-25   11:56 Hrs IST

The inspection took place from April 16 to April 24, 2025, at the subsidiary's manufacturing facility in Farmingdale, New York.

At the end of the inspection, the subsidiary received one observation, documented in the USFDA's Form 483. Notably, the inspection did not raise any concerns regarding data integrity.

Marksans Pharma confirmed that it will work closely with the USFDA to address the observation within the prescribed timeline.

Marksans Pharma is engaged in the research, manufacturing & marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, antidiabetic, pain management, gastroenterological, and anti-allergies. the company is marketing these products globally.

The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24.

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Account Closure | RE-KYC | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures | |Rights & Obligations-English| Rights & Obligations-தமிழ் | Anti Money Laundering Policy | E-Voting | CSR | Voluntary Freezing / Blocking Hit Count : 40507688
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd